Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress

Pharmaceutical Investing

Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM) today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational progress. As quoted in the press release: Mr Glyn Edwards, Chief Executive Officer of Summit, commented: “The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid …

Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM) today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational progress.

As quoted in the press release:

Mr Glyn Edwards, Chief Executive Officer of Summit, commented: “The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy (‘DMD’). These interim data showed a statistically significant and meaningful reduction in both muscle damage and muscle inflammation after just 24 weeks of treatment. Should these changes be sustained after 48 weeks of treatment, we believe we will be positioned to pursue an accelerated path to regulatory approval for ezutromid. We look forward to the full trial results in the third quarter of this year.”

Click here to read the full press release.

Pharmaceutical Investing